|Bid||163.23 x 800|
|Ask||163.25 x 800|
|Day's Range||162.32 - 163.41|
|52 Week Range||114.27 - 197.00|
|Beta (3Y Monthly)||1.98|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 24, 2019 - Jul 29, 2019|
|Forward Dividend & Yield||2.96 (1.78%)|
|1y Target Est||179.79|
A federal judge dealing a blow to the Trump Administration by striking down a new rule that would have forced pharma companies to include the wholesale prices of their drugs in TV ads. Yahoo Finance's Seana Smith and Alexis Keenan discuss.
Allergan (AGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
A federal judge yesterday greenlighted a class-action lawsuit against Allergan subsidiaries Warner Chilcott and Watson for overcharging direct purchasers for Loestrin 24, Minastrin and generic equivalents, according to Hagens Berman. According to the order unsealed July 16, 2019, by Chief Judge William E. Smith of the District of Rhode Island, damages to the class are on the order of $625.2 million – $1.9 billion after automatic trebling under antitrust rules. Trial in the class-action lawsuit is set for January 6, 2020, in Providence, Rhode Island.
DUBLIN, July 17, 2019 /PRNewswire/ -- Allergan plc (AGN), a leading global pharmaceutical company with more than 70 years of heritage in eye care, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for Bimatoprost Sustained-Release (SR). Bimatoprost SR if approved would be the first-in-class sustained-release, biodegradable implant for the reduction of intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension.
Investors will focus on regular top- and bottom-line numbers along with pipeline updates when Novartis (NVS) reports second-quarter results.
Bernstein analyst Ronny Gal says the spread between the current stock price and AbbVie’s offer is fair and it is time to take the foot off the gas.
Alkermes (ALKS) plans to expand the NDA for ALKS 3831 to include the treatment of bipolar I disorder in addition to the treatment for schizophrenia.
NEW YORK, July 12, 2019 -- Halper Sadeh LLP, a global investor rights law firm, is investigating the following companies: Del Frisco’s Restaurant Group, Inc. (NASDAQ: DFRG)The.
J&J's (JNJ) cancer drugs should continue to perform well in second-quarter 2019. Generic/biosimilar headwinds will hurt Pharma unit's sales.
With key drugs losing exclusivity, key drug makers are poised to face deep trouble since their sales are mostly dependent on a single drug.
Intra-Cellular Therapies' (ITCI) lead candidate fails to meet primary endpoint in one of the phase III studies evaluating it in bipolar depression patients. Shares fall.
Allergan plc NYSE:AGNView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for AGN with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting AGN. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $2.71 billion over the last one-month into ETFs that hold AGN are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
AbbVie stock fell on its $63 billion plan to acquire Botox-maker Allergan, which helps the pharmaceutical company diversify as Humira patents expire. So, is ABBV stock a buy right now?
-- Allergan MIND™, Allergan's migraine franchise, showcases data highlighting BOTOX® (onabotulinumtoxinA) for Chronic Migraine, and two investigational products: ubrogepant and atogepant -- -- Pivotal ...
AbbVie's (ABBV) stock suffers a poor run on the bourses due to pipeline setbacks, Humira sales erosion in EU and its proposed offer to buy Allergan.
Editas (EDIT) focuses on the development of its lead candidate, EDIT-101, for treating LCA10, a rare genetic illness that causes blindness. Excessive reliance on partners for revenues remains a woe.